Document is current
Any future updates will be listed below
-
Authors
Faisal, Fahim
Danelakis, Antonios
Bjørk, Marte-Helene
Winsvold, Bendik
Matharu, Manjit
Nachev, Parashkev
Hagen, Knut
,
Tronvik, Erling
Stubberud, Anker
-
Funding
Funding for this research was provided by:
Norges Forskningsråd
Norges Teknisk-Naturvitenskapelige Universitet
UCLH Biomedical Research Centre
NTNU Norwegian University of Science and Technology
- License Information
-
More Information
Article History
Received: 2 March 2025
Accepted: 25 March 2025
First Online: 7 April 2025
Declarations
:
: This study was approved by the Regional Committee for Medical and Health Research (#2015/576/REK Midt and #2014/144/REK Midt).
: Anker Stubberud has received lecture honoraria from TEVA. AS is share-holder and patent holder of Nordic Brain Tech AS and the Cerebri app. ET has received personal fees for lectures/advisory boards: Novartis, Eli Lilly, Abbvie, TEVA, Roche, Lundbeck, Pfizer, Biogen. Consultant for and owner of stocks and IP in Man & Science. Stocks and IP in Nordic Brain Tech and Keimon Medical. Non-personal research grants from several sources, including EU, Norwegian Research Council, Dam foundation, KlinBeForsk. Commissioned research (non-personal): Lundbeck, Eli-Lilly. PN is a shareholder in Hologen. MSM has served on advisory boards for AbbVie, Eli Lilly, Pfizer, Salvia and TEVA; has received payment for educational presentations from AbbVie, Eli Lilly, Organon and TEVA; has received grants from Abbott and Ehlers Danlos Society; stocks in Keilon Medical; and has a patent on system and method for diagnosing and treating headaches (WO2018051103A1, issued).
